Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial. - Wikidata - wikimedia - TriplyDB

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

http://www.wikidata.org/entity/Q37130051

about

Fungal keratitis: The Aravind experience.

P2860

Q47109245-C8018C2D-F5AA-4578-86E7-815B057A4279

P2860

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

http://www.wikidata.org/entity/Q37130051

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@en

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@nl

type

label

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@en

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@nl

prefLabel

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@en

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@nl

P1433

Q37130051-AD68E30F-245E-476F-AB57-639D70108DF8

P1476

Q37130051-6C26915B-0EC2-4813-94EC-1214395A085A

P2093

Q37130051-00DD1FAE-478E-4BA3-98F6-2CDE9D55820F

Q37130051-1A0C3C83-207A-4082-9490-4BC392133FF5

Q37130051-3203AB72-9CF4-4D30-A2BB-63390E22511A

Q37130051-34576332-D3DD-4336-9C6F-FF191A5EF1DF

Q37130051-44EDA8A3-CD59-4514-8640-890C3DF7DD14

Q37130051-55461DF2-5704-46FA-8EF8-BF498459E240

Q37130051-5A18B76B-6FCF-4ECF-AEF5-C6D62D5D6504

Q37130051-5E98FECD-703E-4FB1-AD0E-E2A0501F5CF4

Q37130051-768C1ADA-4680-41FD-9068-C3382350E99B

Q37130051-A300C09D-BA83-45B5-9D99-6113DE1AA3C5

P2860

Q37130051-066BC44F-4AAC-46E8-B62D-09DF3484D014

Q37130051-2D0888E6-E624-46D9-BE09-A1A2299545E1

Q37130051-7B450A2D-08BC-480C-B3AB-0A78181905F6

Q37130051-8A099FF6-4356-4ABF-B12A-1F1BBBA13AE0

Q37130051-924DD9A2-C252-45EF-8C6B-D452593D961B

Q37130051-A8F4B2D9-FD73-4A28-A144-E31C1FB1A3BD

Q37130051-AE013B7A-59D7-4549-A7AA-CC83A8E48093

Q37130051-B7EEE2C8-6224-45F3-8B08-DB1E34CA7426

Q37130051-BD79939D-0C50-4897-9F5F-C72FAC954EFF

Q37130051-CB1A6D3A-FD66-45EF-902C-95FC7E6DF737

P304

Q37130051-71517C85-EE9C-4E71-8122-0B196B7F8638

P31

Q37130051-FB66AF6F-A92B-4898-A6C5-51B49D63EAA8

P356

Q37130051-A6CA4A68-BB01-4155-925A-53B3E104C902

P407

Q37130051-6A7D429E-708A-4051-A20A-2E0C94B810E9

P433

Q37130051-1F80F318-FC84-4D22-9535-FD01508CF099

P478

Q37130051-92C487F8-622B-4DBD-A93D-0B647443031D

P50

Q37130051-4D89D409-CBCE-446D-8B16-6084A85CF207

P577

Q37130051-7D72C575-A8A9-4CF6-A4AD-6C8DFB5EA275

P698

Q37130051-C42CF7AF-74DC-4E01-BE46-713BC0539CDB

P932

Q37130051-7A277F27-D66F-4D3B-995C-BB9090D0FB8D

P356

JAMAOPHTHALMOL.2016.0530

P1433

JAMA Ophthalmology

P1476

Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

@en

P2093

Anita Raghavan

http://www.w3.org/2001/XMLSchema#string

Jennifer Rose-Nussbaumer

http://www.w3.org/2001/XMLSchema#string

Kieran S O'Brien

http://www.w3.org/2001/XMLSchema#string

Michael Zegans

http://www.w3.org/2001/XMLSchema#string

Muthiah Srinivasan

http://www.w3.org/2001/XMLSchema#string

Mycotic Ulcer Treatment Trial Group

http://www.w3.org/2001/XMLSchema#string

N Venkatesh Prajna

http://www.w3.org/2001/XMLSchema#string

Nisha R Acharya

http://www.w3.org/2001/XMLSchema#string

Prajna Lalitha

http://www.w3.org/2001/XMLSchema#string

Revathi Rajaraman

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.

Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India.

Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Association of pretreatment with antifungal medication and fungal resistance in the mycotic ulcer treatment trial I

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.

Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles.

P304

693-696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAOPHTHALMOL.2016.0530

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

Jeremy D Keenan

P577

2016-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27054515

http://www.w3.org/2001/XMLSchema#string

P932

4962688

http://www.w3.org/2001/XMLSchema#string